Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cyclerion Therapeutics (CYCN) EBITDA Margin (2019 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed EBITDA Margin for 6 consecutive years, with 111.54% as the latest value for Q3 2025.

  • For Q3 2025, EBITDA Margin rose 26114.0% year-over-year to 111.54%; the TTM value through Sep 2025 reached 126.2%, up 265112.0%, while the annual FY2024 figure was 181.4%, N/A changed from the prior year.
  • EBITDA Margin hit 111.54% in Q3 2025 for Cyclerion Therapeutics, up from 1797.85% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 27.8% in Q4 2024 and bottomed at 21611.29% in Q1 2021.
  • Average EBITDA Margin over 4 years is 3486.65%, with a median of 1798.77% recorded in 2025.
  • Year-over-year, EBITDA Margin plummeted -1961662bps in 2021 and then soared 1978597bps in 2022.
  • Cyclerion Therapeutics' EBITDA Margin stood at 2690.06% in 2021, then plummeted by -63bps to 4389.87% in 2022, then skyrocketed by 101bps to 27.8% in 2024, then crashed by -501bps to 111.54% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 111.54%, 1797.85%, and 1798.77% for Q3 2025, Q2 2025, and Q1 2025 respectively.